{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
iRhythm Technologies, Inc.
iRhythm Technologies Forms Death Cross, Signaling Potential Bearish Trend Ahead
iRhythm Technologies, Inc. has encountered a technical event known as a Death Cross, indicating a potential bearish trend. Current indicators reflect a negative outlook, despite the company achieving a 19.26% performance over the past year, surpassing the S&P 500. Recent weeks have seen a decline in stock value.
iRhythm Technologies, Inc. Experiences Revision in Stock Evaluation Amid Market Fluctuations
iRhythm Technologies, Inc. has experienced notable stock fluctuations, with a recent closing price of 133.75. The company shows mixed technical indicators, reflecting volatility. Over the past year, it has outperformed the S&P 500, but has faced challenges year-to-date, indicating a complex market position.
iRhythm Technologies Hits Day Low of $135.53 Amid Price Pressure
iRhythm Technologies, Inc. saw a notable stock decline today, contrasting with the S&P 500's gains. Despite recent challenges, the company has shown resilience over the past year, outperforming the index. With a market cap of USD 4,879 million, iRhythm reported significant increases in operating profit and cash flow.
iRhythm Technologies Hits Day Low of $138.03 Amid Price Pressure
iRhythm Technologies, Inc. faced a significant decline in stock value today, marking a challenging trading session. Despite recent fluctuations, the company has demonstrated resilience over the past year with notable operating profit growth and strong net sales, indicating operational strengths amid current market conditions.
iRhythm Technologies Hits New 52-Week High of $210.01, Up 96.89%
iRhythm Technologies, Inc. achieved a new 52-week high of USD 210.01 on October 31, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a significant growth of 96.89% over the past year, despite being loss-making and not offering dividends.
iRhythm Technologies Hits New 52-Week High at $190.86, Up 94.78%
iRhythm Technologies, Inc. achieved a new 52-week high of USD 190.86 on October 29, 2025, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen significant growth over the past year, despite challenges in profitability and a moderate level of leverage.
iRhythm Technologies, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance
iRhythm Technologies, Inc. has recently revised its evaluation amid changing market dynamics. The company’s stock price reflects a slight increase, and it has achieved a notable annual return of 133.88%, significantly outperforming the S&P 500. Mixed technical indicators suggest varying trends in its performance.
Is iRhythm Technologies, Inc. technically bullish or bearish?
As of October 24, 2025, iRhythm Technologies, Inc. has a mildly bullish trend supported by monthly bullish signals, despite some weekly bearish indicators, and has outperformed the S&P 500 year-to-date with a 100.30% return, though it has underperformed over the past five years with a -17.96% return.
Is iRhythm Technologies, Inc. technically bullish or bearish?
As of October 24, 2025, iRhythm Technologies, Inc. shows a mildly bullish trend overall, supported by strong monthly indicators and daily moving averages, despite mixed signals from weekly metrics.
Is iRhythm Technologies, Inc. technically bullish or bearish?
As of October 24, 2025, iRhythm Technologies, Inc. has shifted to a mildly bullish trend, supported by monthly bullish indicators despite some weekly bearish signals, and has significantly outperformed the S&P 500 year-to-date and over the past year, though it has underperformed over the 3-year and 5-year periods.
Is iRhythm Technologies, Inc. technically bullish or bearish?
As of August 1, 2025, iRhythm Technologies, Inc. shows a bullish technical trend with strong indicators, including bullish MACD and moving averages, and has outperformed the S&P 500 significantly over the past month and year-to-date.
Is iRhythm Technologies, Inc. overvalued or undervalued?
As of February 15, 2017, iRhythm Technologies, Inc. is considered risky and overvalued due to its high Price to Book Value, negative EV to EBITDA, and poor ROE, despite a strong recent return, as its long-term performance significantly lags behind the S&P 500.
Is iRhythm Technologies, Inc. overvalued or undervalued?
As of February 15, 2017, iRhythm Technologies, Inc. is considered overvalued and risky, with significant financial distress indicated by a Price to Book Value of 54.03, negative P/E ratio of -70.04, and poor ROE of -76.24%, despite outperforming the S&P 500 with a 46.52% return over the past year.
Is iRhythm Technologies, Inc. technically bullish or bearish?
As of May 2, 2025, iRhythm Technologies, Inc. exhibits a strong bullish trend supported by positive MACD, Bollinger Bands, and moving averages across multiple time frames, alongside a 4.24% weekly return that outperforms the S&P 500.
Who are in the management team of iRhythm Technologies, Inc.?
As of March 2022, the management team of iRhythm Technologies, Inc. consists of independent directors, including Mr. Abhijit Talwalkar (Chairman), Mr. Bruce Bodaken, Ms. Renee Budig, Dr. Cathleen Noel Merz, Mr. Mark Rubash, and Mr. Raymond Scott. They provide governance and oversight for the company.
What does iRhythm Technologies, Inc. do?
iRhythm Technologies, Inc. is a digital health company specializing in biosensor technology and analytics for patient data, with a market cap of approximately $4.63 billion. As of March 2025, it reported net sales of $159 million and a net loss of $31 million.
How big is iRhythm Technologies, Inc.?
As of Jun 18, iRhythm Technologies, Inc. has a market capitalization of $4.63 billion, with net sales of $618.59 million and a net profit of -$98.32 million over the latest four quarters. The company reported shareholder's funds of $90.91 million and total assets of $931.45 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
